Abstract:Objective: Myostatin deletion improves cardiometabolic disease outcomes observed in obesity without any changes in activity in mice. Hormone balance is dysregulated in obesity, resulting in low testosterone and high estradiol levels, which have been shown to correlate with higher risk for developing associated cardiometabolic disease outcomes. However, the basis of these alterations and how they impact factors that improve obese cardiometabolic outcomes are unknown. Methods: Control and obese mice ( db/db) with or without myostatin deletion to induce hypermuscularity were used. Plasme from mice were analyzed for hormone levels via radioimmunoassay (RIA). Aromatase inhibition was performed via dosing 10mg/kg/day via water. Quantitative PCR was used cytochrome P450 enzymes involved in estrogen metabolism in the liver, skeletal muscle, and visceral white adipose tissue. C2C12 overexpression of CYP1B1 and treatment with hydroxyestrogens in vitro was performed and respective enzyme mRNA expression assessed. Results: Deletion of myostatin increased muscle mass by >30% and resulted in and improved glucose tolerance in the context of obesity without any changes in activity. Obesity decreased plasma testosterone 30% and increased estrogen 20% with no change in gonadal weight, which was improved in the absence of myostatin. CYP1B1, an enzyme that converts estradiol to toxic hydroxy estrogens, showed 2.5-fold expression in obese skeletal muscle, which is reduced in the absence of myostatin, with no change in other cytochrome P450s involved in estrogen metabolism. Inhibition of aromatase reduces estrogen and improves testosterone plasma concentration, indicating the excess estrogen in obesity is derived primarily from testosterone conversion. Aromatase expression was increased in obesity but unaffected by changes in muscle mass, this indicates an alteration to downstream estrogen metabolism. In C2C12 cells, overexpression of myostatin recapitulated changes in CYP1B1 expression seen in vivo, suggesting a direct link between the myokine and sex hormone metabolism. In addition, treatment of C2C12 cells with CYP1B1 derived hydroxyestrogens caused a tandem increase in SCD1 expression, indicating a causal link between CYP1B1 activity in obesity to increased triglyceride synthesis. Conclusion: In summary, obesity causes a shift in sex hormone levels towards estrogen production, which is improved by myostatin deletion. A potential mechanism responsible could be altered estrogen metabolism, leading to decreased estrogen levels without restoration of androgen levels. These data suggest CYP1B1 drives the conversion of estrogen to hydroxestrogens, known to harbor carcinogenic and pro-lipidemic influences, in skeletal muscle which may also contribute to cardiometabolic disease. Whether targeting CYP1B1 improves cardiometabolic function in obesity remains to be determined. D.W. Stepp and D.J. Fulton are supported by NIH 1R01HL147159. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Skeletal muscle–targeted delivery of Fgf6 protects mice from diet-induced obesity and insulin resistance

Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle.

Baf60c Drives Glycolytic Metabolism in the Muscle and Improves Systemic Glucose Homeostasis Through Deptor-mediated Akt Activation.

Skeletal muscle-derived exosomal miR-146a-5p inhibits lipogenesis by mediating muscle-fat axis and targeting GDF5-PPARγsignaling

FGF19 protects skeletal muscle against obesity‐induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT‐1/PGC‐α pathway

Skeletal Muscle-Derived Exosomal Mir-146A-5p Inhibits Adipogenesis by Mediating Muscle-Fat Axis and Targeting GDF5-PPARγ Signaling.

Muscle-selective knockout of AMPKα2 does not exacerbate diet-induced obesity probably related to altered myokines expression.

Fibroblast Growth Factor 1 Ameliorates Adipose Tissue Inflammation and Systemic Insulin Resistance Via Enhancing Adipocyte Mtorc2/rictor Signal

The Baf60c/Deptor pathway links skeletal muscle inflammation to glucose homeostasis in obesity.

Metabolic Crosstalk: Molecular Links Between Glycogen and Lipid Metabolism in Obesity

Fibroblast growth factor 6 promotes adipocyte progenitor cell proliferation for adipose tissue homeostasis

FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation

Targeted Deletion of Fibroblast Growth Factor 23 Rescues Metabolic Dysregulation of Diet-induced Obesity in Female Mice

Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice

A Muscle Hypertrophy-Derived Myokine Reprograms the Stromal Vascular Fractions Differentiation Towards Thermogenic Adipocytes in Subcutaneous Adipose Tissue

Fgf6 Promotes Adipocyte Progenitor Cell Proliferation for Adipose Tissue Homeostasis

Myofiber Baf60c controls muscle regeneration by modulating Dkk3-mediated paracrine signaling

Myostatin deletion alters hormone metabolism shifts in obese skeletal muscle of C57/Bl6 mice

Activation of mTORC1 in skeletal muscle regulates whole-body metabolism through FGF21.

Fat Mass- and Obesity-Associated Protein (FTO) Promotes the Proliferation of Goat Skeletal Muscle Satellite Cells by Stabilizing DAG1 mRNA in an IGF2BP1-Related m6A Manner

Endurance Exercise-Induced Fgf21 Promotes Skeletal Muscle Fiber Conversion through TGF-β1 and p38 MAPK Signaling Pathway